BACKGROUND AND OBJECTIVE: Controversy exists regarding the feasibility of preventive clinical trials in prodromal Huntington disease (HD). A primary limitation is a lack of outcome measures for persons with the gene mutation who have not yet been diagnosed with HD. Many longitudinal studies of cognitive decline in prodromal HD have not stratified samples based on disease progression, thereby obscuring differences between symptomatic and nonsymptomatic individuals. METHODS: Prodromal participants from PREDICT-HD were stratified by disease progression into one of three groups: those having a High, Medium, or Low probability of motor manifestation within the next 5 years. Data from a total of N=1299 participants with up to 5950 data points were subjected to linear mixed effects regression on 29 longitudinal cognitive variables, controlling for age, education, depression, and gender. RESULTS: Performance of the three prodromal HD groups was characterised by insidious and significant cognitive decline over time. Twenty-one variables from 19 distinct cognitive tasks revealed evidence of a disease progression gradient, meaning that the rate of deterioration varied as a function of progression level, with faster deterioration associated with greater disease progression. Nineteen measures showed significant longitudinal change in the High group, nine showed significant change in the Medium group and four showed significant cognitive decline in the Low group. CONCLUSIONS: Results indicate that clinical trials may be conducted in prodromal HD using the outcome measures and methods specified. The findings may help inform interventions in HD as well as other neurodegenerative disorders.
BACKGROUND AND OBJECTIVE: Controversy exists regarding the feasibility of preventive clinical trials in prodromal Huntington disease (HD). A primary limitation is a lack of outcome measures for persons with the gene mutation who have not yet been diagnosed with HD. Many longitudinal studies of cognitive decline in prodromal HD have not stratified samples based on disease progression, thereby obscuring differences between symptomatic and nonsymptomatic individuals. METHODS: Prodromal participants from PREDICT-HD were stratified by disease progression into one of three groups: those having a High, Medium, or Low probability of motor manifestation within the next 5 years. Data from a total of N=1299 participants with up to 5950 data points were subjected to linear mixed effects regression on 29 longitudinal cognitive variables, controlling for age, education, depression, and gender. RESULTS: Performance of the three prodromal HD groups was characterised by insidious and significant cognitive decline over time. Twenty-one variables from 19 distinct cognitive tasks revealed evidence of a disease progression gradient, meaning that the rate of deterioration varied as a function of progression level, with faster deterioration associated with greater disease progression. Nineteen measures showed significant longitudinal change in the High group, nine showed significant change in the Medium group and four showed significant cognitive decline in the Low group. CONCLUSIONS: Results indicate that clinical trials may be conducted in prodromal HD using the outcome measures and methods specified. The findings may help inform interventions in HD as well as other neurodegenerative disorders.
Entities:
Keywords:
COGNITION; COGNITIVE NEUROPSYCHOLOGY; HUNTINGTON'S; MOVEMENT DISORDERS
Authors: Eric A Epping; Ji-In Kim; David Craufurd; Thomas M Brashers-Krug; Karen E Anderson; Elizabeth McCusker; Jolene Luther; Jeffrey D Long; Jane S Paulsen Journal: Am J Psychiatry Date: 2015-10-16 Impact factor: 18.112
Authors: Joseph J Shaffer; Ali Ghayoor; Jeffrey D Long; Regina Eun-Young Kim; Spencer Lourens; Lauren J O'Donnell; Carl-Fredrik Westin; Yogesh Rathi; Vincent Magnotta; Jane S Paulsen; Hans J Johnson Journal: Hum Brain Mapp Date: 2017-01-03 Impact factor: 5.038
Authors: Jane S Paulsen; Jeffrey D Long; Christopher A Ross; Deborah L Harrington; Cheryl J Erwin; Janet K Williams; Holly James Westervelt; Hans J Johnson; Elizabeth H Aylward; Ying Zhang; H Jeremy Bockholt; Roger A Barker Journal: Lancet Neurol Date: 2014-11-03 Impact factor: 44.182
Authors: Joy T Matsui; Jatin G Vaidya; Demian Wassermann; Regina Eunyoung Kim; Vincent A Magnotta; Hans J Johnson; Jane S Paulsen Journal: Hum Brain Mapp Date: 2015-07-14 Impact factor: 5.038
Authors: Katherine L Possin; Hosung Kim; Michael D Geschwind; Tacie Moskowitz; Erica T Johnson; Sharon J Sha; Alexandra Apple; Duan Xu; Bruce L Miller; Steven Finkbeiner; Christopher P Hess; Joel H Kramer Journal: Neuropsychologia Date: 2017-04-17 Impact factor: 3.139
Authors: Julia A Rao; Deborah L Harrington; Sally Durgerian; Christine Reece; Lyla Mourany; Katherine Koenig; Mark J Lowe; Vincent A Magnotta; Jeffrey D Long; Hans J Johnson; Jane S Paulsen; Stephen M Rao Journal: Cortex Date: 2014-06-02 Impact factor: 4.027
Authors: Janessa O Carvalho; Jeffrey D Long; Holly J Westervelt; Megan M Smith; Jared M Bruce; Ji-In Kim; James A Mills; Jane S Paulsen Journal: J Clin Exp Neuropsychol Date: 2016 Impact factor: 2.475